BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study to replace painful bone marrow biopsies through a simple...
Read More »Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML
Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with ...
Read More »Isolation and Characterization of CD34+ Blast-Derived Exosomes
Exosomes are membrane-bound vesicles found in all biological fluids. AML patients’ plasma collected at diagnosis contains elevated exosome levels relative to normal donor (ND) plasma. The molecular profile of AML exosomes changes in the course of therapy and may serve ...
Read More »NIH Awards Two Grants in February Supporting Research into microRNAs, Cancer
from GenomeWeb The National Institutes of Health this month awarded two grants worth nearly $300,000 combined to fund research into the role of microRNAs in cancers. The first grant was awarded to Dartmouth College’s Angeline Andrew, who is investigating miRNA ...
Read More »